FDA approves Novartis's CDK4/6 inhibitor

Nature Reviews Drug Discovery 16, 229 (2017). doi:10.1038/nrd.2017.62 Author: Asher Mullard The FDA approved Novartis's ribociclib for the first-line treatment of hormone receptor (HR)+/HER2− advanced breast cancer in combination with an aromatase inhibitor. This is the second approval for the cyclin-dependent kinase 4 and 6 (CDK4/6) class of kinase inhibitors.CDKs

http://feeds.nature.com/~r/nrd/rss/current/~3/dn08tBJnvD0/nrd.2017.62

Source: Nature Reviews Drug Discovery - March 30, 2017 Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research